News | Stents | October 27, 2017

FDA Approves COBRA REDUCE Trial Expansion

Trial will assess safety and efficacy of Cobra PzF NanoCoated Coronary Stent with 14-day DAPT in high bleeding risk patients

FDA Approves COBRA REDUCE Trial of 14-Day DAPT With CeloNova Stent

October 27, 2017 — CeloNova BioSciences Inc. announced the U.S. Food and Drug Administration (FDA) approved expansion of CeloNova's ongoing clinical trial of its proprietary Cobra PzF NanoCoated Coronary Stent (NCS) with 14-day dual antiplatelet therapy (DAPT) in complex patients, such as those who are at high bleeding risk. The COBRA REDUCE trial is the world's first and only randomized control trial to assess 14-day DAPT after percutaneous coronary intervention (PCI), according to the company.

"High-bleeding-risk patients currently have limited stent treatment options available to them primarily due to the duration of DAPT required," stated Robert Byrne, M.D., senior physician at the German Heart Center in Munich, Germany and co-lead investigator of the COBRA REDUCE trial. "The COBRA REDUCE trial aims to provide clinical insights into optimal stent selection and eliminate the compromise between the risk of bleeding or stent thrombosis."

The COBRA REDUCE trial is evaluating whether Cobra PzF NCS with its ultra-pure, ultra-thin Polyzene-F (PzF) fluoropolymer can optimize clinical outcomes with 14-day DAPT as compared to FDA-approved drug-eluting stents (DES) with three or six months of DAPT. The COBRA REDUCE trial will enroll up to 996 patients across 60 centers in the United States and Europe. Clinical data from CeloNova's previous trial, the PzF SHIELD study, demonstrated that Cobra PzF NCS supports very low risk for late ischemic events and low risk for clinically driven total lesion revascularization (TLR) with a short, one-month DAPT minimum.1,2

"The highly-anticipated COBRA REDUCE trial aims to expand upon the SHIELD study's exceptional clinical results and demonstrate Cobra PzF NCS as a safe and effective stent option when combined with 14 days of DAPT," said Donald Cutlip, M.D., executive director of the Baim Institute for Clinical Research (formerly Harvard Research Institute). "I have many patients at high risk of bleeding or who have difficulty maintaining even short-term DAPT regimens. Being able to provide a therapy that is personalized to the patient is of great clinical value." 

Cobra PzF NCS and the COBRA REDUCE trial will be featured in several sessions at the upcoming Transcatheter Cardiovascular Therapeutics (TCT) conference, Oct. 29-Nov. 2, 2017, in Denver. 

For more information: www.celonova.com

Related Content

Shockwave Initiates U.S. Pivotal Study for Coronary Intravascular Lithotripsy
News | Cath Lab | January 16, 2019
Shockwave Medical Inc. has initiated its U.S. Food and Drug Administration (FDA) Investigational Device Exemption (IDE...
National Academy of Engineering, Ohio University Award 2019 Russ Prize
News | Cath Lab | January 03, 2019
Ohio University and the National Academy of Engineering announced the 2019 Fritz J. and Dolores H. Russ Prize will be...
Videos | Cath Lab | January 03, 2019
This is walk through inside one of the cardiac hybrid cath labs at the...
Videos | Cath Lab | January 03, 2019
This is the newest cardiac cath lab at the ...
Study Finds Effective Treatment for Coronary Slow Flow
News | Cath Lab | December 27, 2018
Patients who arrive at the hospital with heart-attack-like symptoms have had little recourse for their chest pain if...
Shockwave Announces Collaboration With Abiomed on Physician Training
News | Cath Lab | December 14, 2018
Shockwave Medical announced a new investment and collaboration agreement with Abiomed Inc. As outlined by the agreement...
Sponsored Content | Videos | Cath Lab | October 24, 2018
Michael Flaherty, M.D., discusses a study published in Circulation Research which finds that use of hemodynamic suppo
Philips Showcases Integrated Solutions for Cardiovascular Care at TCT 2018
News | Cath Lab | September 20, 2018
At the Transcatheter Cardiovascular Therapeutics (TCT) annual meeting, Sept. 21–25 in San Diego, Philips is showcasing...
Overlay Init